BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31811561)

  • 1. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden.
    Brusselaers N; Sadr-Azodi O; Engstrand L
    J Gastroenterol; 2020 Apr; 55(4):453-461. PubMed ID: 31811561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
    Brusselaers N; Wahlin K; Engstrand L; Lagergren J
    BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study.
    Kamal H; Sadr-Azodi O; Engstrand L; Brusselaers N
    Hepatology; 2021 Oct; 74(4):2021-2031. PubMed ID: 34018229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
    Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
    Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of proton pump inhibitors and risk of pancreatic cancer.
    Hicks B; Friis S; PottegÄrd A
    Pharmacoepidemiol Drug Saf; 2018 Aug; 27(8):926-930. PubMed ID: 29923251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
    Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
    BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden.
    Ngwenya S; Simin J; Brusselaers N
    Dig Dis Sci; 2023 Jun; 68(6):2252-2263. PubMed ID: 36629968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance proton pump inhibition therapy and risk of oesophageal cancer.
    Brusselaers N; Engstrand L; Lagergren J
    Cancer Epidemiol; 2018 Apr; 53():172-177. PubMed ID: 29477057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs for peptic ulcer disease and GERD.
    Treat Guidel Med Lett; 2011 Sep; 9(109):55-60; quiz 2 p following 60. PubMed ID: 21860368
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
    Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
    Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Doorakkers E; Lagergren J; Engstrand L; Brusselaers N
    Gut; 2018 Dec; 67(12):2092-2096. PubMed ID: 29382776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea.
    Seo SI; Park CH; You SC; Kim JY; Lee KJ; Kim J; Kim Y; Yoo JJ; Seo WW; Lee HS; Shin WG
    Gut; 2021 Nov; 70(11):2066-2075. PubMed ID: 33975868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication.
    Graham DY; Hammoud F; El-Zimaity HM; Kim JG; Osato MS; El-Serag HB
    Aliment Pharmacol Ther; 2003 May; 17(10):1229-36. PubMed ID: 12755836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term continuous use of proton-pump inhibitors is associated with renal function decline in patients without acute kidney injury.
    Hatakeyama Y; Horino T; Matsumoto T; Terada Y; Okuhara Y
    Clin Exp Nephrol; 2021 Oct; 25(10):1087-1092. PubMed ID: 34089392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison table: Drugs for GERD and peptic ulcer disease.
    Med Lett Drugs Ther; 2018 Jan; 60(1538):e16-e18. PubMed ID: 29309400
    [No Abstract]   [Full Text] [Related]  

  • 16. Drugs for GERD and peptic ulcer disease.
    Med Lett Drugs Ther; 2018 Jan; 60(1538):9-16. PubMed ID: 29309399
    [No Abstract]   [Full Text] [Related]  

  • 17. Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden.
    Brusselaers N; Lagergren J
    BMJ Open; 2018 Jul; 8(7):e021869. PubMed ID: 29982219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of Helicobacter pylori does not decrease the long-term use of acid-suppressive medication.
    Tan AC; Hartog GD; Mulder CJ
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1519-22. PubMed ID: 10571610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer.
    Hu FL; Jia JC; Li YL; Yang GB
    J Int Med Res; 2003; 31(6):469-74. PubMed ID: 14708410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
    Landi SN; Sandler RS; Pate V; Lund JL
    Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.